The bill increases patent-eligibility clarity and preserves incentives for certain biotech developments while expanding the scope of eligible subject matter in ways that may raise low-quality patents, litigation risk, and costs for small businesses and software innovators.
Researchers, inventors, and patent applicants get clearer, more predictable patent-eligibility rules (including a requirement that courts assess claims as a whole), reducing inconsistent rejections and improving the ability to plan R&D and commercialization.
Biotech firms, small businesses, and researchers can obtain patents on purified, enriched, or otherwise altered genes and natural materials (while unmodified human genes remain unpatentable), preserving incentives for development of biologics and altered natural products.
Patent applicants and the public gain clearer statutory limits on when adding generic or incidental computer steps will not revive patent eligibility, which should reduce low-quality software patents and improve patent quality for software-related claims.
Small businesses, tech companies, and the public may face more patents on business, software, and social processes because broader eligibility could allow claims on many such methods, increasing litigation risk and compliance/licensing costs.
Tech workers and small inventors face higher risk of low-quality patents because limiting courts and the USPTO from considering whether claim elements are conventional may permit patents on routine implementations, driving downstream licensing and enforcement costs.
Biotech companies, hospitals, and purchasers of natural-product therapies could see reduced proprietary protection for unmodified natural materials (despite protections for altered materials), which may reduce investment incentives or shift business models and pricing in natural-product markets.
Based on analysis of 4 sections of legislative text.
Eliminates judicial eligibility exceptions and replaces section 101 to broadly allow patents for any "useful" invention while listing specific ineligible categories and carve-outs.
Rewrites federal patent-eligibility law to eliminate judicially created exceptions and make any "useful" process, machine, manufacture, composition of matter, or useful improvement generally patentable, while listing specific categories that remain ineligible. It preserves novelty, nonobviousness, and written-description/definiteness requirements as separate substantive hurdles, adds a statutory definition of "useful," clarifies how courts must evaluate eligibility (claim as a whole, without relying on sections 102/103/112), and includes carve-outs and limits such as allowing eligibility when practical performance requires a machine and excluding mere computer pre/post-processing from rescuing ineligible subject matter.
Introduced May 1, 2025 by Kevin Kiley · Last progress May 1, 2025